Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".

Abstract

BACKGROUND:

Psoriasis vulgaris is a common disease that follows a chronic course. So far, few studies have addressed outcome methods which evaluate the benefits of drugs and medical devices by measuring patient preferences.

OBJECTIVE:

Assessment of patients' outcomes using the "Patient benefit index" (PBI), a validated goal attainment scaling tool, in the treatment of psoriasis. Data were obtained within an epidemiological study in 2,009 patients with psoriasis vulgaris and/or psoriatic arthritis.

METHODS:

Cross-sectional study in 133 nationwide German dermatological practices and hospital departments. The following were recorded a) in the doctors' questionnaire--previous treatments and diseases, clinical characteristics and psoriasis area and severity index (PASI), b) in the patients' questionnaire--quality of life (LQ), patient-relevant therapeutic benefits and satisfaction with care.

RESULTS:

On average, patients achieved a total PBI of 2.5±1.1. 86.7% of patients showed a more than minimum benefit (PBI>1). Patients treated with biologicals had a higher benefit (mean PBI 3.0) than patients in other groups (e.g. PBI 2.6 in systemics).

CONCLUSION:

PBI values indicate that systemic agents and biologics are of high therapeutic benefit to the vast majority of patients. The development of the PBI has enabled a decisive step to be taken in the area of scientifically-based outcome assessments.

• Authors: Marc Alexander Radtke, Ines Schäfer, Christine Blome, Matthias Augustin
• Journal: European journal of dermatology : EJD (Eur J Dermatol) Vol. 23 Issue 2 Pg. 212-7 (Apr 01 2013) ISSN: 1952-4013 [Electronic] France
• PMID: 23587940 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Dermatologic Agents

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Biological Therapy
• Cross-Sectional Studies
• Dermatologic Agents (therapeutic use)
• Female
• Germany
• Humans
• Male
• Middle Aged
• PUVA Therapy
• Patient Satisfaction
• Psoriasis (drug therapy)
• Quality of Life
• Severity of Illness Index
• Surveys and Questionnaires
• Treatment Outcome
• Young Adult